Sona Nanotech Inc (SONA) AI Stock Analysis

• Market Cap: C$55.37M
• Dividend Yield: N/A
• Average Volume (3M): 124.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.13
• Revenue Growth: N/A
• EPS Growth: 10.97%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 113,005,360
• 10 Day Avg. Volume: 87,178
• 30 Day Avg. Volume: 124,263
• PEG Ratio: 1.33
• Price to Book (P/B): 10.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.08
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: ―

Sona Nanotech's overall stock score reflects significant financial challenges with zero revenue and ongoing losses, which heavily weigh down its financial performance and valuation. However, the stock's neutral technical momentum and promising corporate developments in cancer therapy offer some optimism for future growth potential.

Positive Factors

Innovative Cancer Therapy

The promising preclinical results of Sona's Targeted Hyperthermia Therapy (THT) in cancer treatment could position the company as a leader in innovative therapies, enhancing its market position and long-term growth potential in the medical sector.

Strategic Presentations

Presenting at major conferences like the Canadian Melanoma Conference increases Sona's visibility and credibility in the medical community, potentially leading to new partnerships and market opportunities.

Stock Option Grants

The allocation of stock options to directors and officers aligns management's interests with shareholders, potentially driving long-term strategic decisions that enhance shareholder value.

Negative Factors

Zero Revenue

The absence of revenue generation poses a significant challenge to Sona's financial stability and limits its ability to invest in growth and innovation, potentially impacting its long-term viability.

Negative Cash Flow

Persistent negative cash flow indicates reliance on external funding, which can be unsustainable and may hinder the company's ability to finance future projects or withstand economic downturns.

High Liabilities

High liabilities and a poor debt-to-equity ratio suggest financial instability, which can limit Sona's operational flexibility and increase the risk of insolvency if not addressed.

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.

How the Company Makes Money

Sona Nanotech Inc generates revenue primarily through the sale of its proprietary nanomaterials, including gold nanorods, which are utilized in the production of diagnostic assays and other medical technologies. The company monetizes its technology by supplying these nanomaterials to diagnostic test manufacturers, research institutions, and healthcare companies. Additionally, Sona Nanotech may engage in licensing agreements and partnerships with other organizations to expand the application of its technologies and reach new markets. While direct sales of its nanomaterials form the core revenue stream, strategic collaborations and research grants may also contribute to the company's earnings.

Sona Nanotech Inc Financial Statement Overview

Summary

Sona Nanotech Inc. is facing severe financial challenges with zero revenue and consistent losses. Despite some improvement in stockholders' equity, the company struggles with high liabilities and negative cash flows, indicating ongoing financial instability.

Income Statement

Sona Nanotech Inc. has consistently reported zero revenue over multiple periods, indicating a significant challenge in generating sales. The company has experienced persistent negative gross profit and net income, leading to negative profit margins. The EBIT and EBITDA margins are also deeply negative, reflecting high operating losses.

Balance Sheet

Despite a challenging income statement, Sona Nanotech has managed to improve its stockholders' equity, turning positive in the most recent TTM period. However, the company still faces high liabilities and a concerning debt-to-equity ratio. The equity ratio is improving but remains low, suggesting potential financial instability.

Cash Flow

The company reports negative operating and free cash flow but has seen an increase in financing activities, indicating reliance on external funding. The free cash flow growth rate remains negative, reflecting ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-364.29K	-733.98K	-457.00K	-60.32K	-65.59K	-66.37K
EBITDA	-2.18M	-2.00M	-2.02M	-2.34M	-10.38M	-6.24M
Net Income	-2.94M	-2.70M	-2.50M	-2.36M	-10.77M	-6.27M
Balance Sheet
Total Assets	2.29M	3.75M	2.75M	520.77K	1.52M	724.63K
Cash, Cash Equivalents and Short-Term Investments	731.00K	1.86M	115.38K	164.42K	1.20M	110.78K
Total Debt	421.77K	394.67K	527.68K	608.47K	1.34M	1.49M
Total Liabilities	1.28M	1.24M	1.59M	1.03M	2.75M	4.16M
Stockholders Equity	1.01M	2.51M	1.16M	-507.86K	-1.22M	-3.44M
Cash Flow
Free Cash Flow	-2.35M	-1.96M	-1.26M	-1.81M	-3.81M	-4.75M
Operating Cash Flow	-2.35M	-1.96M	-1.26M	-1.81M	-3.81M	-4.05M
Investing Cash Flow	0.00	0.00	14.64K	0.00	0.00	-694.01K
Financing Cash Flow	3.05M	3.70M	1.20M	―	4.89M	4.27M

Sona Nanotech Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Neutral. The current price of 0.49 is above the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.51, and below the 200-day MA of 0.50, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.99 is Neutral, neither overbought nor oversold. The STOCH value of 53.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	47 Neutral	C$49.39M	-29.94	―	―	-21.89%	26.36%
EBM	44 Neutral	C$56.14M	-135.83	―	―	-9.02%	14.29%
MIR	42 Neutral	C$48.84M	-12.07	―	―	-41.70%	-35.42%
SONA	40 Underperform	C$55.37M	-17.43	-2846.90%	―	―	10.97%

Sona Nanotech Inc Corporate Events

Sona Nanotech to Host Webinar on Innovative Cancer Therapy Clinical Study

Sona Nanotech Inc. has announced an upcoming investor webinar to discuss its early feasibility clinical study for the Targeted Hyperthermia Therapy, a novel cancer treatment. This study involves ten advanced melanoma patients who have not responded to standard immunotherapy, highlighting Sona’s commitment to advancing cancer treatment options. The webinar aims to provide insights into the study’s progress and potential impact, positioning Sona as a key player in innovative cancer therapies.